Skip to main content
SpringerLink
Log in

Cancer

A targeted treatment with off-target risks

  • News & Views
  • Published:

From Nature

View current issue Submit your manuscript

This article has been updated

It emerges that blood-cancer-targeting drugs that block a tumour-survival pathway also activate a mutation-causing enzyme in mice and in human cells. This might have implications for the clinical use of these drugs. See Letter p.489

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Inhibition of a B-cell-receptor signalling pathway might increase the number of harmful mutations.

Change history

  • 22 February 2017

    A new reference 10 has been added, in acknowledgement of the fact that this paper was the first to report that PI3Kδ suppresses expression of AID.

Notes

  1. See all news & views

References

  1. Luo, J., Solimini, N. L. & Elledge, S. J. Cell 136, 823–837 (2009).

    Article  CAS  Google Scholar 

  2. Compagno, M. et al. Nature 542, 489–493 (2017).

    Article  ADS  CAS  Google Scholar 

  3. Wiestner, A. Haematologica 100, 1495–1507 (2015).

    Article  CAS  Google Scholar 

  4. Ten Hacken, E. & Burger, J. A. Clin. Cancer Res. 20, 548–556 (2014).

    Article  CAS  Google Scholar 

  5. Okkenhaug, K. & Burger, J. A. Curr. Top. Microbiol. Immunol. 393, 123–142 (2016).

    CAS  PubMed  Google Scholar 

  6. Byrd, J. C. et al. N. Engl. J. Med. 369, 32–42 (2013).

    Article  CAS  Google Scholar 

  7. Furman, R. R. et al. N. Engl. J. Med. 370, 997–1007 (2014).

    Article  CAS  Google Scholar 

  8. Smith, M. R. Expert Opin. Pharmacother. 16, 1879–1887 (2015).

    Article  CAS  Google Scholar 

  9. Lamanna, N. & O'Brien, S. Hematol. Am. Soc. Hematol. Educ. Prog. 2016, 137–145 (2016).

    Article  Google Scholar 

  10. Omori, S. A. et al. Immunity 25, 545–557 (2006).

    Article  CAS  Google Scholar 

  11. Zhang, T. et al. J. Allergy Clin. Immunol. 122, 811–819 (2008).

    Article  CAS  Google Scholar 

  12. Chandra, V., Bortnick, A. & Murre, C. Trends Immunol. 36, 527–535 (2015).

    Article  CAS  Google Scholar 

  13. Fruman, D. A., Satterthwaite, A. B. & Witte, O. N. Immunity 13, 1–3 (2000).

    Article  CAS  Google Scholar 

  14. O'Brien, S. M. et al. 58th ASH Annu. Meet. Expos. Abstr. 233 (2016); see go.nature.com/2kssjo8

Download references

Author information

Authors and Affiliations

  1. David A. Fruman is in the Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, California 92697, USA.,

    David A. Fruman

  2. Susan O'Brien is at the Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92868, USA.,

    Susan O'Brien

Authors
  1. David A. Fruman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan O'Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Fruman.

Ethics declarations

Competing interests

The authors declare competing financial interests. See online article for details.

Related links

Related links

Related links in Nature Research

Cancer: A gene-expression profile for leukaemia

Cancer genomics: Spot the difference

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fruman, D., O'Brien, S. A targeted treatment with off-target risks. Nature 542, 424–425 (2017). https://doi.org/10.1038/nature21504

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature21504

  • Springer Nature Limited

This article is cited by

Search

Navigation